Peijia Medical Limited (4WO) - Net Assets
Based on the latest financial reports, Peijia Medical Limited (4WO) has net assets worth €1.86 Billion EUR (≈ $2.17 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.66 Billion ≈ $3.11 Billion USD) and total liabilities (€798.71 Million ≈ $933.77 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Peijia Medical Limited to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.86 Billion |
| % of Total Assets | 69.94% |
| Annual Growth Rate | N/A |
| 5-Year Change | -38.46% |
| 10-Year Change | N/A |
| Growth Volatility | 7.68 |
Peijia Medical Limited - Net Assets Trend (2018–2025)
This chart illustrates how Peijia Medical Limited's net assets have evolved over time, based on quarterly financial data. See 4WO days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Peijia Medical Limited (2018–2025)
The table below shows the annual net assets of Peijia Medical Limited from 2018 to 2025. For live valuation and market cap data, see Peijia Medical Limited stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €1.86 Billion ≈ $2.17 Billion |
-9.12% |
| 2024-12-31 | €2.04 Billion ≈ $2.39 Billion |
-10.09% |
| 2023-12-31 | €2.27 Billion ≈ $2.66 Billion |
-13.78% |
| 2022-12-31 | €2.64 Billion ≈ $3.08 Billion |
-12.64% |
| 2021-12-31 | €3.02 Billion ≈ $3.53 Billion |
+7.32% |
| 2020-12-31 | €2.81 Billion ≈ $3.29 Billion |
+603.98% |
| 2019-12-31 | €-558.21 Million ≈ $-652.60 Million |
-491.71% |
| 2018-12-31 | €-94.34 Million ≈ $-110.29 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Peijia Medical Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 437459400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €6.36 Billion | 344.82% |
| Total Equity | €1.84 Billion | 100.00% |
Peijia Medical Limited Competitors by Market Cap
The table below lists competitors of Peijia Medical Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Xinning Modern Logist
SHE:300013
|
$319.47 Million |
|
Shandong Sito Bio-technology Co Ltd
SHE:300583
|
$319.51 Million |
|
YUEXIU SERVICES GROUP LTD
F:5R9
|
$319.64 Million |
|
Materialise NV
NASDAQ:MTLS
|
$319.66 Million |
|
Silence Therapeutics PLC
NASDAQ:SLN
|
$319.30 Million |
|
Citizens Financial Services Inc. Common Stock
NASDAQ:CZFS
|
$319.29 Million |
|
Tehmag Foods
TWO:1264
|
$319.27 Million |
|
STP&I Public Company Limited
BK:STPI
|
$319.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Peijia Medical Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,028,043,000 to 1,844,476,000, a change of -183,567,000 (-9.1%).
- Net loss of 203,287,000 reduced equity.
- New share issuances of 8,952,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-203.29 Million | -11.02% |
| Share Issuances | €8.95 Million | +0.49% |
| Other Changes | €10.77 Million | +0.58% |
| Total Change | €- | -9.05% |
Book Value vs Market Value Analysis
This analysis compares Peijia Medical Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.15x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €-0.15 | €0.41 | x |
| 2019-12-31 | €-0.92 | €0.41 | x |
| 2020-12-31 | €4.44 | €0.41 | x |
| 2021-12-31 | €4.53 | €0.41 | x |
| 2022-12-31 | €3.92 | €0.41 | x |
| 2023-12-31 | €3.37 | €0.41 | x |
| 2024-12-31 | €3.05 | €0.41 | x |
| 2025-12-31 | €2.75 | €0.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Peijia Medical Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -28.52%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.44x
- Recent ROE (-11.02%) is above the historical average (-18.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | €-73.19 Million |
| 2019 | 0.00% | -2844.95% | 0.02x | 0.00x | €-476.16 Million |
| 2020 | -73.53% | -5351.59% | 0.01x | 1.02x | €-2.35 Billion |
| 2021 | -19.02% | -420.57% | 0.04x | 1.05x | €-876.13 Million |
| 2022 | -15.46% | -162.58% | 0.08x | 1.26x | €-671.57 Million |
| 2023 | -17.26% | -88.98% | 0.17x | 1.17x | €-619.94 Million |
| 2024 | -11.17% | -36.81% | 0.23x | 1.33x | €-429.38 Million |
| 2025 | -11.02% | -28.52% | 0.27x | 1.44x | €-387.73 Million |
Industry Comparison
This section compares Peijia Medical Limited's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $53,882,823,829
- Average return on equity (ROE) among peers: -35.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Peijia Medical Limited (4WO) | €1.86 Billion | 0.00% | 0.43x | $319.35 Million |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $16.74 Billion | 1.48% | 0.47x | $152.32K |
| BIORETEC OY (0TN) | $1.92 Million | -125.78% | 0.82x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $464.53 Billion | 11.55% | 0.43x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $703.81 Million | 25.76% | 0.12x | $711.77 Million |
| HeraMED Limited (1I4) | $2.59 Million | -168.10% | 0.60x | $28.30 Million |
| Medtronic PLC (2M6) | $395.90 Million | 21.85% | 0.62x | $83.04 Billion |
| AVITA Medical Inc (51KB) | $115.66 Million | -22.98% | 0.09x | $172.49 Million |
| BRAINCOOL AB (5YL) | $116.23 Million | -39.24% | 0.15x | $21.56 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.33 Billion | -20.20% | 0.10x | $107.57 Million |
About Peijia Medical Limited
Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People's Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company's products inc… Read more